Reaction Details |
![](/images/Email.png) | Report a problem with these data |
Target | Mitogen-activated protein kinase 9 |
---|
Ligand | BDBM50204832 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_447121 (CHEMBL897420) |
---|
IC50 | 37±n/a nM |
---|
Citation | Raboisson, P; Lenz, O; Lin, TI; Surleraux, D; Chakravarty, S; Scholliers, A; Vermeiren, K; Delouvroy, F; Verbinnen, T; Simmen, K Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorg Med Chem Lett17:1843-9 (2007) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Mitogen-activated protein kinase 9 |
---|
Name: | Mitogen-activated protein kinase 9 |
Synonyms: | JNK-55 | JNK2 | JNK2/JNK3 | MAPK9 | MK09_HUMAN | Mitogen-Activated Protein Kinase 9 (JNK2) | Mitogen-activated protein kinase 8/9 | PRKM9 | SAPK1A | Stress-activated protein kinase JNK2 | c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 2 (JNK2) |
Type: | Enzyme |
Mol. Mass.: | 48131.49 |
Organism: | Homo sapiens (Human) |
Description: | JNK-2 was purchased from Upstate Cell Signaling Solutions (formerly Upstate Biotechnology). |
Residue: | 424 |
Sequence: | MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRP
FQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIH
MELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNF
MMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQ
LGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSK
MLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEV
MDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPL
EGCR
|
|
|
BDBM50204832 |
---|
n/a |
---|
Name | BDBM50204832 |
Synonyms: | 4-(2-(5-bromo-2-fluorophenyl)pteridin-4-ylamino)-N-(3-(2-oxopyrrolidin-1-yl)propyl)nicotinamide | CHEMBL234655 |
Type | Small organic molecule |
Emp. Form. | C25H22BrFN8O2 |
Mol. Mass. | 565.397 |
SMILES | Fc1ccc(Br)cc1-c1nc(Nc2ccncc2C(=O)NCCCN2CCCC2=O)c2nccnc2n1 |
Structure |
|